Figure 6.

Wee1 and mTOR inhibition significant delay ovarian cancer growth in PDX models. A. Tumor volume curves tumor burden changes of patient-derived xenografts. Mice treated with vehicle (5% DMSO+30% PEG300+5% Tween 80+ddH₂O), AZD1775 (60 mg/kg, oral gavage, per day), AZD2014 (20 mg/kg, oral gavage, per day), or a combination of AZD1775 and AZD2014. Data across studies represent mean ± SD of three independent experiments, p-value from one-way ANOVA: ****P < 0.0001. B. Photographs of tumors in each group of patient-derived xenografts after sacrifice. C. Representative histologic sections of xenografts from tumors of PDX were immunohistochemical staining with p-S6 (Ser235/236) (left). Percent of p-S6 (Ser235/236) positive cells (right). Student’s t-test: *P < 0.05, **P < 0.01. D. Representative histologic sections of xenografts from tumors of PDX were immunohistochemical staining with p-RPA32 (S4/S8) (left). Percent of p-RPA32 (S4/S8) positive cells (right). Student’s t-test: *P < 0.05, ***P < 0.001. E. Representative histologic sections of xenografts from tumors of PDX were immunohistochemical staining with γH2AX (S139) (left). Percent of γH2AX (S139) positive cells (right). Student’s t-test: n.s as nonsense, **P < 0.01. F. Representative histologic sections of xenografts from tumors of PDX were immunohistochemical staining with Ki67 (left). Percent of Ki67 positive cells (right). Student’s t-test: *P < 0.05, ***P < 0.001.